MedTrace Logo

Antithrombotic Management of Acute Mesenteric Ischaemia

NCT05706012 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2024-05-09

No results posted yet for this study

Summary

Guidelines on the acute and long-term pharmacological treatment of acute mesenteric ischaemia (AMI) recommend the use of thrombolytic, antiplatelet or anticoagulant therapy depending on the aetiology of AMI and the use of stenting but only few details are given on the choice of the drug, dose and duration of treatment. Besides, recommendations are mainly based on data on coronary, cerebral and other peripheral artery diseases and do also not take into account the altered drug absorption in patients with short bowel syndrome, in which AMI can result.This case-based survey will inform us on the current international clinical practice of long-term antithrombotic management of AMI.

Conditions

  • Acute Mesenteric Ischemia
  • Short Bowel Syndrome

Interventions

OTHER

Survey

Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-02-29
Completion
2024-02-29

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05706012 on ClinicalTrials.gov